FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2574293854> ?p ?o ?g. }

• W2574293854 endingPage "s481" @default.
• W2574293854 startingPage "s475" @default.
• W2574293854 abstract "Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary immunodeficiency disease (PI) from intravenous (IVIG) therapy to most subcutaneous therapy ([SCIG], except the 10% SCIG human hyaluronidase and immune globulin). However, a dose ratio of 1:1 was studied and approved for the European Union (EU). The dose-adjustment ratio used by prescribers in real-world US clinical practice is unknown.To examine real-world Hizentra 20% SCIG-to-IVIG dose ratios in the US after PI patients are switched from IVIG to 20% SCIG (Hizentra).A retrospective longitudinal study was conducted using prescription shipment data of patients with PI from specialty pharmaceutical and service providers from 2011 to 2016. Patients who had at least 1 shipment of IVIG prior to switching to 20% SCIG (Hizentra) and subsequently received at least 1 more 20% SCIG (Hizentra) shipment in the following 6 months were included. Monthly 20% SCIG (Hizentra) doses following a switch from IVIG were calculated for each 2-month interval by summing daily doses that were estimated by dividing shipped volume by days between shipments. Mean monthly IVIG dose was calculated from the total volume shipped prior to switch. Per-patient dose ratios of Hizentra 20% SCIG-to-IVIG were calculated by dividing monthly 20% SCIG (Hizentra) dose by monthly IVIG dose during each 2-month interval. To minimize the influence of outliers, median dose ratios were reported. Dose ratios at months 2 to 4, 4 to 6, and 6 to 8 were compared with the dose ratio at months 0 to 2 using the Wilcoxon signed rank test. A sensitivity analysis excluding pediatric patients was conducted to assess the impact of changes in weight.Data from 278 patients who met the inclusion criteria showed that median Hizentra 20% SCIG-to-IVIG dose ratios were 1.14:1 at 0 to 2 months post switch, 1.09:1 at 2 to 4 months, and stabilized at 1.05:1 at 4 to 6 and 6 to 8 months post switch. Median dose ratios at months 2 to 4, 4 to 6, and 6 to 8 were statistically significantly lower than the median dose ratio at 0 to 2 months post switch (all P < .001). Similar results were seen in the sensitivity analysis excluding pediatric patients.Real-world data indicate that patients were switched to 20% SCIG (Hizentra) from IVIG at dose ratios lower than recommended by US prescribing information but similar to prescribing information in the EU. The initial dose ratio of 1.14:1 at 0 to 2 months stabilized to 1.05:1 at 4 to 6 and 6 to 8 months, which was consistent with reports of dose-equivalent switching patterns used in management of PI in clinical practice in the US." @default.
• W2574293854 created "2017-01-26" @default.
• W2574293854 creator A5011177968 @default.
• W2574293854 creator A5019444135 @default.
• W2574293854 creator A5034135253 @default.
• W2574293854 creator A5046303279 @default.
• W2574293854 creator A5049944206 @default.
• W2574293854 creator A5063896009 @default.
• W2574293854 creator A5078940298 @default.
• W2574293854 creator A5091766832 @default.
• W2574293854 date "2016-10-01" @default.
• W2574293854 modified "2023-09-26" @default.
• W2574293854 title "Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy." @default.
• W2574293854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27849353" @default.
• W2574293854 hasPublicationYear "2016" @default.
• W2574293854 type Work @default.
• W2574293854 sameAs 2574293854 @default.
• W2574293854 citedByCount "2" @default.
• W2574293854 countsByYear W25742938542019 @default.
• W2574293854 countsByYear W25742938542022 @default.
• W2574293854 crossrefType "journal-article" @default.
• W2574293854 hasAuthorship W2574293854A5011177968 @default.
• W2574293854 hasAuthorship W2574293854A5019444135 @default.
• W2574293854 hasAuthorship W2574293854A5034135253 @default.
• W2574293854 hasAuthorship W2574293854A5046303279 @default.
• W2574293854 hasAuthorship W2574293854A5049944206 @default.
• W2574293854 hasAuthorship W2574293854A5063896009 @default.
• W2574293854 hasAuthorship W2574293854A5078940298 @default.
• W2574293854 hasAuthorship W2574293854A5091766832 @default.
• W2574293854 hasConcept C126322002 @default.
• W2574293854 hasConcept C159654299 @default.
• W2574293854 hasConcept C187212893 @default.
• W2574293854 hasConcept C203014093 @default.
• W2574293854 hasConcept C2426938 @default.
• W2574293854 hasConcept C2779019163 @default.
• W2574293854 hasConcept C2779134260 @default.
• W2574293854 hasConcept C2909916134 @default.
• W2574293854 hasConcept C44249647 @default.
• W2574293854 hasConcept C71924100 @default.
• W2574293854 hasConcept C98274493 @default.
• W2574293854 hasConceptScore W2574293854C126322002 @default.
• W2574293854 hasConceptScore W2574293854C159654299 @default.
• W2574293854 hasConceptScore W2574293854C187212893 @default.
• W2574293854 hasConceptScore W2574293854C203014093 @default.
• W2574293854 hasConceptScore W2574293854C2426938 @default.
• W2574293854 hasConceptScore W2574293854C2779019163 @default.
• W2574293854 hasConceptScore W2574293854C2779134260 @default.
• W2574293854 hasConceptScore W2574293854C2909916134 @default.
• W2574293854 hasConceptScore W2574293854C44249647 @default.
• W2574293854 hasConceptScore W2574293854C71924100 @default.
• W2574293854 hasConceptScore W2574293854C98274493 @default.
• W2574293854 hasIssue "15 Suppl" @default.
• W2574293854 hasLocation W25742938541 @default.
• W2574293854 hasOpenAccess W2574293854 @default.
• W2574293854 hasPrimaryLocation W25742938541 @default.
• W2574293854 hasRelatedWork W2065430497 @default.
• W2574293854 hasRelatedWork W2075979923 @default.
• W2574293854 hasRelatedWork W2096797471 @default.
• W2574293854 hasRelatedWork W2154386650 @default.
• W2574293854 hasRelatedWork W2172111759 @default.
• W2574293854 hasRelatedWork W2324036447 @default.
• W2574293854 hasRelatedWork W2735157618 @default.
• W2574293854 hasRelatedWork W2899396768 @default.
• W2574293854 hasRelatedWork W2942723308 @default.
• W2574293854 hasRelatedWork W3008810734 @default.
• W2574293854 hasVolume "22" @default.
• W2574293854 isParatext "false" @default.
• W2574293854 isRetracted "false" @default.
• W2574293854 magId "2574293854" @default.
• W2574293854 workType "article" @default.